Madurella mycetomatis mycetoma treated successfully with oral voriconazole

Lacroix, Claire; Kerviler, É. de; Morel, Patrice; Derouin, F.; Chauvin, M. Feuilhade de

doi:10.1111/j.1365-2133.2005.06534.x

Cited by 60 publications

(27 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most experience has been with ketoconazole and itraconazole, though itraconazole appears to have more consistent clinical activity (9,27,30,116,127). Recently, reports of success using voriconazole and posaconazole have been published (431,447,462,537). Therapy generally is continued for at least 3 months, though courses of 6 to 24 months or longer are often required.…”

Section: Eumycetomamentioning

confidence: 99%

Melanized Fungi in Human Disease

2010

View full text Add to dashboard Cite

SUMMARY Melanized or dematiaceous fungi are associated with a wide variety of infectious syndromes. Many are soil organisms and are generally distributed worldwide, though certain species appear to have restricted geographic ranges. Though they are uncommon causes of disease, melanized fungi have been increasingly recognized as important pathogens, with most reports occurring in the past 20 years. The spectrum of diseases with which they are associated has also broadened and includes allergic disease, superficial and deep local infections, pneumonia, brain abscess, and disseminated infection. For some infections in immunocompetent individuals, such as allergic fungal sinusitis and brain abscess, they are among the most common etiologic fungi. Melanin is a likely virulence factor for these fungi. Diagnosis relies on careful microscopic and pathological examination, as well as clinical assessment of the patient, as these fungi are often considered contaminants. Therapy varies depending upon the clinical syndrome. Local infection may be cured with excision alone, while systemic disease is often refractory to therapy. Triazoles such as voriconazole, posaconazole, and itraconazole have the most consistent in vitro activity. Further studies are needed to better understand the pathogenesis and optimal treatment of these uncommon infections.

show abstract

Section: Eumycetomamentioning

confidence: 99%

Melanized Fungi in Human Disease

2010

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the second case of S. apiospermum eumycetoma successfully treated with voriconazole 13 . This drug has been used in a few cases of eumycetoma 1,6,10 , and although expensive it should be considered a first-line antifungal agent for the treatment of eumycetoma caused by S. apiospermum. The dose required and the duration of the course for optimum therapy should be investigated.…”

Section: Clinical Casementioning

confidence: 99%

Scedosporium apiospermum EUMYCETOMA SUCCESSFULLY TREATED WITH ORAL VORICONAZOLE: REPORT OF A CASE AND REVIEW OF THE BRAZILIAN REPORTS ON SCEDOSPORIOSIS

Oliveira

Unis

Hochhegger

et al. 2013

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…Anastrozole and letrozole, two highly effective azole inhibitors that target CYP19A1 (aromatase), have recently been recommended as the first line chemotherapy for estrogen-dependent breast cancer (10,11). Additionally, azole antifungal agents have been used successfully for decades to treat fungal diseases (12,13). However, targeting a particular P450 enzyme selectively, while avoiding off-target effects on other host P450 enzymes, is both difficult and challenging, as many of the currently marketed azole antifungal agents are also potent inhibitors of oxidative liver drug metabolism (14).…”

mentioning

confidence: 99%

“…In this study, we focus on CYP119, a thermophilic cytochrome P450 enzyme from Sulfolobus acidocaldarius, because of its inherent stability, a conformational range akin to that of the mammalian P450 enzymes, and its suitability for NMR studies (34,35). Previously, we investigated ligand-induced conformational changes in the F-G region of CYP119 by 1 H, 13 C HSQC NMR after incorporating 13 C-labeled 4-methoxyphenylalanine at the Phe-144, Phe-153, or Phe-162 positions (34,35). The labeled proteins were studied with a low affinity inhibitor (imidazole), a high affinity inhibitor (4-phenylimidazole, 4-PI), 2 and a high affinity substrate (lauric acid).…”

mentioning

confidence: 99%